Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan
· Delayed Price · Currency is TWD 48.00
+0.40 (0.84%)
Apr 29, 2026, 1:10 PM CST
Medigen Vaccine Biologics Revenue
In the year 2025, Medigen Vaccine Biologics had annual revenue of 613.17M TWD with 1.24% growth. Medigen Vaccine Biologics had revenue of 147.01M in the quarter ending December 31, 2025, with 14.14% growth.
Revenue
613.17M
Revenue Growth
+1.24%
P/S Ratio
25.52
Revenue / Employee
5.95M
Employees
103
Market Cap
15.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 613.17M | 7.53M | 1.24% |
| Dec 31, 2024 | 605.64M | 216.01M | 55.44% |
| Dec 31, 2023 | 389.62M | 24.58M | 6.73% |
| Dec 31, 2022 | 365.04M | -2.92B | -88.87% |
| Dec 31, 2021 | 3.28B | 3.27B | 28,413.03% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AP Biosciences | 32.25M |
| Polaris Group | 40.60M |
| EirGenix | 1.01B |
| TaiMed Biologics | 611.35M |
| Locus Cell | 12.74M |
| Lumosa Therapeutics | 35.83M |
| Sunmax Biotechnology | 2.03B |
| Ever Supreme Bio Technology | 1.02B |